Viridian Biosciences
Viridian is a biopharma incubator, founded to strengthen the link between scientific discovery and product commercialization. Viridian leverages validated scientific findings and a deep appreciation of evolving unmet needs to identify opportunities with strong underlying science, de-risking translational data, and a high unmet need. Upon validation of these “program hypotheses”, Viridian establishes new companies, led initially by the Viridian team, to pursue the discovery and development of first-in-class or best-in-class new molecules.
Quellis Biosciences
Series A in 2019
Quellis Biosciences, Inc. is a biopharmaceutical company headquartered in Waltham, Massachusetts, established in 2017. The company is dedicated to developing new monoclonal antibody therapies aimed at treating rare diseases, particularly for patients who lack effective treatment options. By focusing on next-generation antibody therapies, Quellis seeks to enhance patient outcomes and deliver innovative solutions that address unmet medical needs. Through its research and development efforts, the company aims to optimize therapeutic leads and identify promising antibodies, ultimately improving the quality of life for individuals affected by serious rare conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.